Organon & Co.
Moat Score — Organon & Co.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Decades-old brand recognition (Fosamax, Singulair, Zetia, Nexplanon) and regulatory/manufacturing know-how across six owned global sites provide real but modest protection, since most Established Brands products have already lost patent exclusivity and Nexplanon's core patents expire in 2027-2030. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Organon has some manufacturing scale from inherited Merck sites, but it is not a low-cost generics producer; in biosimilars it must match or beat rivals like Sandoz and Samsung Bioepis on cost, and in Established Brands it competes against dedicated generics makers (Teva, Viatris) that are typically cheaper. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Unlike patent-protected innovator pharma, Organon's pricing power is weak: Established Brands revenue is declining annually from generic erosion, biosimilars by design compete on undercutting originator prices, and global policy pressure (U.S. IRA negotiations, China VBP rounds cutting prices over 50%, EU reference pricing) caps realized prices nearly everywhere. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceuticals and biosimilars carry no network effect — a medicine's value to one patient is unaffected by how many other patients or physicians use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Women's Health products create genuine switching friction: Nexplanon and other LARC devices require a clinical insertion/removal procedure, and established fertility and contraception regimens carry real behavioral and prescriber inertia, though this does not extend to the Established Brands or Biosimilars segments. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Organon's global commercial footprint (140+ countries, ~$6.2B revenue) provides some scale efficiency, but the business is fragmented across three segments with different dynamics, carries a heavy debt load (~$8.6B) from the Merck spinoff, and lacks the concentrated, self-reinforcing scale of a single dominant blockbuster franchise. |